COGNITION THERAPEUTICS

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

23 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

08 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation

02 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

13 May 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

11 May 2022 06:00:01 By Nasdaq GlobeNewswire

CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

04 May 2022 16:54:44 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

04 May 2022 15:01:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

03 May 2022 07:00:03 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

25 Apr 2022 15:01:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

25 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

06 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

30 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results

22 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022

10 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in March Investment Conferences

08 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

08 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

10 Jan 2022 06:30:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in Next-Generation Alzheimer’s Disease Panel at Virtual Biotech Showcase on January 11, 2022

21 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation

30 Nov 2021 06:30:00 By Nasdaq GlobeNewswire